ljc 10627 has been researched along with cefoselis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bale, MJ; Erwin, ME; Jones, RN | 1 |
| Houston, AK; Jones, RN | 1 |
2 other study(ies) available for ljc 10627 and cefoselis
| Article | Year |
|---|---|
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control S
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ceftizoxime; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quality Control; Quinolones; Reference Values; Spiro Compounds; Thienamycins | 1994 |
Post-antibiotic effect of FK-037 and biapenem tested against five bacterial species.
Topics: Ceftizoxime; Enterobacter cloacae; Enterococcus faecium; Escherichia coli; Gram-Negative Bacteria; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins | 1994 |